Related Experiment Video
Updated: Dec 13, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Left Atrial Appendage Occlusion: Past, Present and Future
Wern Yew Ding1,2, John Mandrola3, Dhiraj Gupta1,2
1Liverpool Centre for Cardiovascular Science, Department of Cardiology, University of Liverpool, Liverpool, United Kingdom.
Insights
Left atrial appendage (LAA) occlusion is a promising alternative to oral anticoagulation for stroke prevention in atrial fibrillation (AF) patients unsuitable for blood thinners. More research is needed to confirm its long-term effectiveness and cost-efficiency.
Area of Science:
- Cardiology
- Medical Devices
- Interventional Procedures
Background:
- Oral anticoagulation is often unsuitable for stroke prevention in atrial fibrillation (AF) patients.
- Percutaneous left atrial appendage (LAA) occlusion has emerged as a significant alternative.
- Existing data suggest favorable outcomes, leading to guideline recommendations for specific patient groups.
Purpose of the Study:
- To evaluate the role and efficacy of LAA occlusion in AF patients.
- To address the lack of prospective controlled trials for LAA occlusion.
- To investigate the cost-effectiveness of LAA occlusion in high-risk patient populations.
Main Methods:
- Review of registry and cohort study data on LAA occlusion outcomes.
- Analysis of existing cost-effectiveness modeling studies.
- Identification of research gaps, particularly in prospective trials and high-risk patient cohorts.
Main Results:
- Registries and cohort studies show favorable short- and long-term outcomes for LAA occlusion.
- International guidelines recommend LAA occlusion for AF patients with contraindications to oral anticoagulation.
- Prospective controlled trials are currently lacking in this population.
Conclusions:
- LAA occlusion is a promising strategy for stroke prevention in AF patients with contraindications to oral anticoagulation.
- Further research, including prospective trials, is essential to define its exact role and long-term efficacy.
- Cost-effectiveness needs further investigation, especially in high-risk patients with limited long-term survival.
Abstract:
There are several situations whereby oral anticoagulation may be unsuitable for stroke prevention in patients with atrial fibrillation (AF). Percutaneous left atrial appendage (LAA) occlusion has received much attention in this area. Various devices have already been developed and tested for this purpose. Data from registries and cohort studies have indicated favourable short- and long-term outcomes with LAA occlusion, and several international guidelines recommend its use in AF patients with contraindications to oral anticoagulation. However, prospective controlled trials in this very population are lacking. Furthermore, while modelling studies on cost analyses have suggested that LAA occlusion may be a cost-effective strategy compared with standard medical therapy, these have not been performed in high-risk patients who may have limited survival in the medium to long term. Thus, while LAA occlusion offers promise, there is a strong need for additional research to investigate its exact role, its long-term outcomes and cost efficacy.
